Azithromycin effectiveness against intracellular infections of Francisella
© Ahmad et al; licensee BioMed Central Ltd. 2010
Received: 25 November 2009
Accepted: 23 April 2010
Published: 23 April 2010
Macrolide antibiotics are commonly administered for bacterial respiratory illnesses. Azithromycin (Az) is especially noted for extremely high intracellular concentrations achieved within macrophages which is far greater than the serum concentration. Clinical strains of Type B Francisella (F.) tularensis have been reported to be resistant to Az, however our laboratory Francisella strains were found to be sensitive. We hypothesized that different strains/species of Francisella (including Type A) may have different susceptibilities to Az, a widely used and well-tolerated antibiotic.
In vitro susceptibility testing of Az confirmed that F. tularensis subsp. holarctica Live Vaccine Strain (LVS) (Type B) was not sensitive while F. philomiragia, F. novicida, and Type A F. tularensis (NIH B38 and Schu S4 strain) were susceptible. In J774A.1 mouse macrophage cells infected with F. philomiragia, F. novicida, and F. tularensis LVS, 5 μg/ml Az applied extracellularly eliminated intracellular Francisella infections. A concentration of 25 μg/ml Az was required for Francisella- infected A549 human lung epithelial cells, suggesting that macrophages are more effective at concentrating Az than epithelial cells. Mutants of RND efflux components (tolC and ftlC) in F. novicida demonstrated less sensitivity to Az by MIC than the parental strain, but the tolC disc-inhibition assay demonstrated increased sensitivity, indicating a complex role for the outer-membrane transporter. Mutants of acrA and acrB mutants were less sensitive to Az than the parental strain, suggesting that AcrAB is not critical for the efflux of Az in F. novicida. In contrast, F. tularensis Schu S4 mutants ΔacrB and ΔacrA were more sensitive than the parental strain, indicating that the AcrAB may be important for Az efflux in F. tularensis Schu S4. F. novicida LPS O-antigen mutants (wbtN, wbtE, wbtQ and wbtA) were found to be less sensitive in vitro to Az compared to the wild-type. Az treatment prolonged the survival of Galleria (G.) mellonella infected with Francisella.
These studies demonstrate that Type A Francisella strains, as well as F. novicida and F. philomiragia, are sensitive to Az in vitro. Francisella LPS and the RND efflux pump may play a role in Az sensitivity. Az also has antimicrobial activity against intracellular Francisella, suggesting that the intracellular concentration of Az is high enough to be effective against multiple strains/species of Francisella, especially in macrophages. Az treatment prolonged survival an in vivo model of Francisella- infection.
Bacteria in the Francisella genus are nonmotile, nonsporulating, gram-negative coccobacilli. Francisella causes a zoonotic disease; humans can become infected via a variety of mechanisms including inhalation of an extremely low infectious dose . F. tularensis primarily targets macrophages where bacterial survival and replication occurs . The genus Francisella is divided into two species: tularensis and philomiragia. Francisella tularensis has four subspecies: F. tularensis subspecies tularensis (formerly F. tularensis,) F. tularensis subspecies holarctica (which includes the live vaccine strain, LVS), F. tularensis subspecies mediasiatica, and F. tularensis subspecies novicida (F. novicida) . Subspecies of Francisella tularensis are further separated into two types depending on their virulence. Type A strains include Francisella tularensis subspecies tularensis Schu S4 (F. tularensis Schu S4) and are more virulent , except for the ATCC type strain F. tularensis subsp. tularensis NIH B38 which is avirulent [4–6]. Francisella Type A strains are normally associated with ticks and rabbits and are restricted to North America. Type B strains (Francisella tularensis subspecies holarctica and mediasiatica) are less virulent and cause tularemia throughout Eurasia .
Standard recommended antibiotic treatment for tularemia includes oral tetracycline antibiotics (e.g. doxycycline) and fluoroquinolones (e.g. ciprofloxacin) which have adverse side-effects on pediatric and the elderly patients, and individuals with liver disease. Aminoglycosides such as streptomycin and gentamicin can be injected intravenously or intramuscularly , but are not commonly used. Macrolides are oral antibiotics commonly used to treat bacterial respiratory illnesses. Azithromycin (Az), a member of the azalide subclass of macrolides, binds to the 50 s subunit of gram-negative bacterial ribosomes, and inhibits translation of mRNA resulting in inhibition of bacterial growth or death . It has been suggested that the two basic amine sites of Az interact with the negatively charged heptose-phosphate region of lipopolysaccharide (LPS) in order to enter gram-negative bacteria . F. novicida transposon insertion mutants in the genes involved in lipopolysaccharide (LPS) production (wbtN, wbtE, wbtQ and wbtA) were tested to determine if there might be a role of LPS in Az binding and penetration. Mutations in genes responsible for the synthesis of the O-antigen in F. novicida have been previously shown to decrease virulence and resistance to serum killing while macrophage uptake and replication remained unaffected .
Az, which is commonly prescribed to pediatric patients for treatment of common upper respiratory track and ear infections , has low toxicity and few side-effects . When administered, the antibiotic becomes ion-trapped in the acidic lysosomes of white blood cells including macrophages resulting in a high intracellular concentration compared to the plasma during the dose period. Intracellular concentrations remain high after the dose period ends with a half-life of 68 hours .
Murine macrophages J774A.1 are a well-studied in vitro model system for tularemia [19, 20] and were chosen as a model cell system to study Francisella infection and treatment by Az. The murine macrophage cell line J774A.1 supports the intracellular replication of F. tularensis LVS , F. novicida, and F. tularensis Schu S4 . For a model of the human system, human lung epithelial cells A549 were chosen. F. tularensis LVS has been previously shown to infect and replicate within A549 cells [22–24]. We hypothesized that the ability of Az to concentrate at high levels within the macrophages may result in effectiveness against intracellular infections by Francisella species, even at extracellular Az levels lower than the MIC.
The larval stage of Galleria (G.)mellonella, wax moth caterpillar, has been used as a model to study infections caused by some bacteria including F. tularensis LVS . The larvae do not have an adaptive immune system, but have resistance to microbial infections via cellular and humoral defenses . The analysis of insect responses to pathogens can provide an accurate indication of the mammalian response to that pathogen. Physical effects such as color change can be observed when the bacteria replicates and increases in the larvae . We used G. mellonella as an alternative to the mouse model of Francisella infection to test our hypothesis that Az treatment could prolong the survival of Francisella infected caterpillars.
Francisella's sensitivity to Az
It has been reported that European clinical strains of Type B F. tularensis are resistant to Az . However, we observed that commonly used laboratory strains of Francisella are sensitive to Az. In vitro susceptibility testing of Az confirmed that F. tularensis LVS strain was not highly sensitive in vitro to this antibiotic, confirming that the Type B strains are relatively resistant to this antibiotic. Our study demonstrated that F. philomiragia, F. novicida and Type A F. tularensis tularensis, including both F. tularensis tularensis NIH B38 and F. tularensis Schu S4 strains, were susceptible to this drug in vitro and in vivo.
Az Disk Inhibition Assay with Francisella strains.
Antibiotic Zone of Inhibition (mm) (Disc is 6 mm)
F. tularensis LVS
6.0 ± 0
28.7 ± 0.7
21.7 ± 0.8
F. tularensis NIH B38
45.9 ± 6.2
F. tularensis Schu S4
25.5 ± 1.9
MIC Assay of Az for Francisella strains.
Az MIC (μg/ml)
Gent MIC (μg/ml)
F. tularensis LVS
F. tularensis Schu S4
A549 cell cytotoxicity.
0 μg/ml Az
0.1 μg/ml Az
1.0 μg/ml Az
2.5 μg/ml Az
5.0 μg/ml Az
0 ± 3.0
2.9 ± 2.8
8.0 ± 4.0
18.3 ± 5.2
19.7 ± 9.6
0 ± 2.3
4.1 ± 5.0
3.3 ± 6.3
9.6 ± 5.4
17.8 ± 13.2
0 ± 1.3
0 ± 2.5
7.1 ± 4.6
1.7 ± 3.2
8.5 ± 4.1
F. tularensis LVS
0 ± 3.7
2.12 ± 5.0
4.6 ± 5.9
8.4 ± 5.1
5.2 ± 5.6
Francisella LPS mutants
Az Disk Inhibition Assay with Francisella transposon mutants of LPS production genes.
Antibiotic No Growth Zone (mm)
28.7 ± 0.7
20.8 ± 0.5
23.3 ± 0
23.0 ± 0.9
20.1 ± 1.3
MIC Assay of Az for F. novicida transposon mutants.
AZ MIC (μg/ml)
F. tularensis Schu S4
Francisella RND mutants
Az Disk Inhibition Assay with Francisella transposon RND Efflux mutants.
Antibiotic No Growth Zone (mm)
31.4 ± 1.0
28.0 ± 3.1
33.2 ± 1.4
30.7 ± 1.2
23.5 ± 0.7
25.2 ± 1.1
F. tularensis Schu S4
25.5 ± 1.9
41.7 ± 2.7
35.7 ± 4.3
In the disc inhibition assay of the disulfide bond protein mutant dsbB, there was no significant difference compared to the wild-type (p-value = 0.162) (Table 6). Similarly, the MIC for dsbB was not significantly different than the wild-type value (p-value = 0.400) (Table 5). Thus, mutation of dsbB does not seem to have a significant impact on the ability of the organism to resist Az, whereas transposon insertion mutants in the tolC, ftlC, acrA and acrB components of the RND efflux system appear to decrease the sensitivity of F. novicida to Az. This result for tolC and ftlC may be in contrast to Gil et al. , who found that F. tularensis LVS deletion of tolC or ftlC did not alter the sensitivity to erythromycin (15 μg disc). The MIC of F. tularensis LVS is higher than can be achieved using a 15 μg disc, reported at >256 μg/ml erythromycin . Therefore, any alteration in sensitivity due to tolC deletion would not be observed at this low concentration of antibiotic.
In contrast to the F. novicida results, the F. tularensis Schu S4 ΔacrA mutant and ΔacrB mutants had greater sensitivity to Az compared to the wild-type F. tularensis Schu S4 (p-value < 0.001) (Table 6). This is consistent with the findings of Qin et al.  who found an increased sensitivity of ΔacrB to 50 μg disc erythromycin. The MICs for Az against F. tularensis Schu S4 RND efflux mutants were also determined. The MICs for ΔacrA and ΔacrB (MIC > 1.5 μg/ml Az) are higher than the wild-type MIC of 0.78 μg/ml Az (p-value < 0.02) (Figure 4C, Table 5). However, the F. tularensis Schu S4 mutants for ΔacrA (EC50 of 0.085 μg/ml) and ΔacrB (EC50 0f 0.049 μg/ml) have EC50s less than the wild-type F. tularensis Schu S4 (EC50 of 0.145 μg/ml), reflecting the altered shape of the MIC curve and indicating increased sensitivity. Only ΔacrB was statistically significantly different for EC50 when compared to the wild-type F. tularensis Schu S4 (p-value < 0.05). Thus, F. tularensis Schu S4 ΔacrA and ΔacrB mutants had greater sensitivity to Az compared to F. novicida mutants, or the parental F. tularensis Schu S4 strain by disc inhibition assay and MIC.
Az inhibition of intracellular Francisella mutant strains
G. mellonella infection by Francisella and antibiotic treatment
The macrolide erythromycin has limited efficacy against many gram-negative bacteria due to its hydrophobic nature and lack of permeability of the gram-negative outer membrane . The sensitivity of erythromycin varies between Francisella strains. In the North American Type A Francisella strains, erythromycin MICs range from 0.5 to 4 μg/ml, while F. tularensis LVS has an MIC > 256 μg/ml . The macrolide azithromycin is more effective against gram-negative bacteria than erythromycin . Despite reports that European clinical strains of Type B F. tularensis are resistant to Az (MIC > 256 mg/L) , we observed that commonly used laboratory strains were sensitive to Az. In this study, we have demonstrated that the Type A F. tularensis tularensis strains are sensitive to Az in vitro. F. philomiragia and F. novicida are also sensitive with similar MICs. We determined that the MIC for F. tularensis LVS (NR-646) was 25 ug/ml Az, confirming the finding that LVS is relatively more resistant to Az than other Francisella strains.
Az is pumped out of gram-negative bacteria by several drug-efflux systems, including the RND efflux pumps. Az sensitivity differed between F. novicida and F. tularensis Schu S4 RND efflux mutants. Wild-type F. tularensis Schu S4 has similar sensitivity to Az as wild-type F. novicida, but the RND efflux mutants ΔacrA and ΔacrB in F. tularensis Schu S4 are more sensitive to Az, whereas the F. novicida acrA and acrB mutants are more resistant. These F. tularensis Schu S4 ΔacrA and ΔacrB mutants were also reported to be more sensitive to the related antibiotic erythromycin . The difference between the F. tularensis Schu S4 and the F. novicida mutants might be due to the fact that F. tularensis Schu S4 has 254 pseudogenes; many of these genes are intact in F. novicida. For example, in F. tularensis Schu S4, at least 14 genes of the MFS transporter superfamily contain stop codons or frameshifts [34, 35] and are thus predicted to be non-functional. Additional types of transporter proteins, including a drug-resistance transporter (FTT1618), are also reported to be non-functional pseudogenes  in F. tularensis Schu S4. It could be that the remaining TolC-AcrAB pump is the major means by which F. tularensis Schu S4 pumps out Az. If this pump is compromised, the organism would be more susceptible to the antibiotic, because it may not have an operational alternative pump, such as the MFS or ABC transporters to pump out the drug. This is supported by the finding that ΔacrA and ΔacrB mutants in F. tularensis Schu S4 also displayed increased sensitivity to nalidixic acid (a substrate for the MFS transporter), as well as detergents, streptomycin, tetracycline, and other molecules . In the case of F. novicida, there may be alternate systems that can pump out the drug in the absence of the RND system. Alternatively, the mutation in acrA or acrB may cause an up-regulation of expression of another drug-efflux pump, rendering the bacteria more resistant to the antibiotic [36, 37]. Previous studies have shown that dsbB mutant in F. tularensis Schu S4 does not have any effect on antibiotic sensitivity (including the macrolide erythromycin) . Consistent with the F. tularensis Schu S4 dsbB mutant, the F. novicida dsbB mutant showed no difference from the wild-type F. novicida.
Another common mechanism of resistance to macrolides is modification of the 23S rRNA. It has been reported that F. tularensis LVS has a point mutation in Domain V of the 23S rRNA, rendering it more resistant to erythromycin than F. novicida or F. tularensis Schu S4 . This modification could also explain the increased resistance to Az in F. tularensis LVS. In addition, there are methylases that can confer increased resistance by targeted modification (methylation) of a specific adenine residue of the 23S rRNA. There are some methylases that have been identified as critical virulence factors for Francisella that might carry out this modification . Some methylases that are present in the genome of F. novicida are either absent or are pseudogenes/nonfunctional genes (such as FTT0010, FTT0770, FTT1430, FTT1719, and FTT1735c) in F. tularensis Schu S4, potentially contributing to the different sensitivities to Az between the strains . Any potential role of these molecules in Az sensitivity or resistance in Francisella has not yet been determined.
It has been suggested that Az attaches to the acidic LPS on the outer membrane of gram-negative bacteria, allowing the drug to penetrate through the outer membrane and enter the bacteria . The wbt locus in Francisella, which is responsible for the production of LPS O-antigen, has been shown to be required for virulence . In published reports, the wbtA mutant in F. tularensis LVS demonstrated a loss of the O-antigen and an inability to replicate in mouse macrophages. F. novicida wbtA mutants replicate normally and have only moderate sensitivity to serum [42, 43]. We tested F. novicida transposon-insertion mutants wbtN, wbtE, wbtQ and wbtA, which are involved in the production of LPS, and found that these mutants were less susceptible to Az. Mutations of the LPS in the F. novicida transposon LPS O-antigen mutants may alter the LPS region presumed to bind to Az, resulting in a decreased amount of Az penetration and increased resistance to Az. Our results support the proposed role of LPS O-antigen in Az penetration into gram-negative bacteria such as Francisella.
Az is a weak base that can remain inside host cells for a longer time at a higher concentration than in the serum. This occurs because the basic amine groups of Az neutralize the lysosomal pH and prevent acidification of the lysosome. This process causes the drug to become trapped in the cell due to the positive charge. The drug is slowly released from polymorphonuclear neutrophils, allowing for a long half-life . Az also concentrates in macrophages, which suggested to us that it might be useful as a potential treatment of intracellular pathogens such as F. tularensis. J774A.1 mouse macrophage were infected with F. philomiragia, F. novicida, and F. tularensis LVS and treated with Az. It was determined that 5 μg/ml Az was effective in eliminating intracellular F. philomiragia, F. novicida, and even F. tularensis LVS infections in J774A.1 cells. Although Type B strains are intrinsically more resistant to macrolides, F. tularensis LVS CFUs were eliminated below the Az MIC values for this strain. We suggest that J774A.1 cells can sufficiently concentrate Az so that the intramacrophage concentration of Az exceeds the MIC. Thus, it may be that Az is effective against LVS in vivo due to the concentration effect in macrophages. A concentration of 25 μg/ml Az was found to be effective against Francisella infections in A549 cells, suggesting that these non-phagocytic cells may be less able to concentrate the antibiotic intracellularly .
Az treatment has not been tested sufficiently in the clinic to know if it can be used to treat tularemia infection. In one reported case, the patient's illness was fatal after treatment by Az, trimethoprim-sulfamethoxazole, streptomycin, and ceftriaxone of F. tularensis, suggesting that the patient was extremely ill when treatment was initiated. In another case, the patient's symptoms decreased with a one day ceftriaxone treatment followed by a 5 day Az treatment, but symptoms recurred after the treatment was completed . There have been several reports of successful treatment with erythromycin, giving credence to the sensitivity of Type A strains to the macrolide class of antibiotics [46, 47]. To test the in vivo effectiveness of Az against Francisella infections, we employed the wax-moth caterpillar model . The time-course of infection of the caterpillars closely matched the published report. We extended the published report by demonstrating that wax-moth caterpillars can also be infected by F. novicida. We demonstrated that a single injection of Az increased the mean survival time of Francisella infected G. mellonella and is more effective than a similar dose of ciprofloxacin. Within a host, macrolides, including Az, inhibit the production of cytokines that cause inflammation and prevent the accumulation of neutrophils, which suggests immunomodulatory effects separate from their antibacterial effects . It has been shown that after Francisella infection in mice, there is a delayed response in the induction of host proinflammatory cytokines and recruitment of inflammatory cells to the site of infection, resulting in uncontrolled bacterial replication . G. mellonella, however, does not have a similar immune response following Francisella infection. Since the therapeutic efficacy of Az cannot be observed in G. mellonella, future experiments will be conducted using a mouse model. Our results demonstrate efficacy of Az against multiple different Francisella strains and species. In future work, we will extend the Az studies to murine infections with the fully virulent strain, F. tularensis Schu S4.
Az and other macrolide antibiotics may have a secondary benefit to patients with pneumonic tularemia infection since they also have immunomodulatory functions. Az has been used to treat non-infectious respiratory diseases such as diffuse panbronchiolitis (an inflammatory lung disease) and has been shown to reduce cytokine responses in the lungs thereby lessening the acute inflammatory response [48, 50], even at sub-antimicrobial doses. Az is also used in the long-term management of lung transplant patients, including those with bronchiolitis obliterans syndrome, a disease occasionally resulting from the chronic immunological and inflammatory status in some post-transplant lungs . Pulmonary tularemia often exhibits a robust pro-inflammatory response. If Az proves to be effective against F. tularensis in vivo, it may provide a dual therapeutic effect by also mitigating the pro-inflammatory response. Thus, there may be additional non-antimicrobial benefits to the lung as a result of using Az to treat pulmonary tularemia, which is often complicated by robust pro-inflammatory responses.
The current established treatment protocol for tularemia in children is ciprofloxacin . However, ciprofloxacin has the potential for significant side effects, including liver toxicity, tendonitis and renal failure [40, 53, 54]. Az (trade name: Zithromax) is commonly prescribed to pediatric patients for ear infections and other common gram-negative infections, with very safe outcomes . With the finding that Az concentrates in macrophages and is effective against Francisella species (including LVS) in vitro and in an in vivo infection model, we propose that further studies be done to establish the clinical utility of Az against tularemia, as an alternative treatment. In case of a deliberate tularemia infection of the population, such as in a biological weapons attack, there may be patients who can not tolerate the standard treatment. Az could be tested either as a stand-alone therapy or in combination with other chemotherapeutic agents. Developing an alternate effective therapy to treat tularemia in patients that do not tolerate ciprofloxacin well, such as pediatric and elderly patients, will lead to safer therapeutic options for physicians.
The antibiotics investigated in this study were azithromycin (Az) (Biochemika), gentamicin (ATCC), and ciprofloxacin (Biochemika). Az was obtained as 15 μg discs (Fluka # 68601 or Remel # R33105), and dry powder (Fluka). Az was dissolved in distilled water and ciprofloxacin was dissolved in 0.5 M HCl to appropriate concentration. Gentamicin was obtained in solution at high concentration (50 mg/ml, ATCC) and diluted in distilled water.
F. novicida and F. tularensis subsp. tularensis Schu S4 mutants used.
Hypothetical protein FTN_0779
Membrane fusion protein FTN_1609
Membrane fusion protein FTN_1609
RND efflux transporter, AcrB/AcrD/AcrF family FTN_1610
RND efflux transporter, AcrB/AcrD/AcrF family FTN_1610
Schu S4 ΔacrB  (FTT0105c)
Schu S4 ΔacrA  (FTT0106c)
Mouse macrophage cells J774A.1 (ATCC #TIB-67) and human lung epithelial cells A549 (ATCC #CCL-185) were obtained from ATCC, Manassas, VA. J774A.1 cells were grown in Dulbecco's Modified Eagle Medium (DMEM) with 10% fetal bovine serum and passed every 3 days in a 1:3 dilution following manufacturers' instructions. A549 cells were grown in Ham's F-12 with 10% fetal bovine serum and passed every 3 days in a 1:3 dilution.
Disc inhibition assay
Kirby-Bauer disc inhibition assay protocol was followed . 100 μl of overnight bacterial cultures were spread on Chocolate II agar and Schu S4 strains were spread on Mueller-Hinton agar plate with three discs each containing 15 μg Az placed in a triangle and incubated based on length of time for bacterial growth to be seen on the plate: 24 (for F. novicida, F. philomiragia, and F. tularensis Schu S4), 48 (for F. tularensis LVS), and 72 hours (for F. tularensis NIH B38) at 37°C in 5% CO2. The diameter of the zone of inhibition including the 6 mm disc was measured (in mm) with three independent measurements for each zone (n = 9). Inhibition was defined as the area of no bacterial growth around the discs. A reading of 6 mm indicates no inhibition .
Minimal inhibitory concentration (MIC)
Assays were performed with small modification following published protocols . The MIC for F. novicida, F. philomiragia, F. tularensis LVS, related F. novicida mutants, F. tularensis Schu S4, and related F. tularensis Schu S4 mutants were determined in TSB-C media by antibiotic dilution in triplicates. The broth was then inoculated with 105 CFU/ml per strain. Concentration of the antibiotics ranged from 1 mg/ml to 0.0001 μg/ml. The MIC was read at optical density 600 nm after 24 hours (for F. philomiragia, F. novicida, and F. tularensis Schu S4) and after 48 hours (for F. tularensis LVS) and was defined as the lowest concentration of antibiotic with no visible growth.
Data analysis and statistics
Y corresponds to bacterial mortality (% OD, where zero drug = 100%) at a given antibiotic concentration (μg/ml), with X being the logarithm of that concentration (log μg/ml). In the equation, "Top" and "Bottom" refer to the upper and lower boundaries, and were constrained to values <100% and >0%, respectively. EC50 values were determined by fitting the data from the antimicrobial assays to a standard sigmoidal dose-response curve (Equation 1) with a Hill slope of 1. Control samples with no antibiotic are plotted as 10^-4 μg/ml for graphing purposes. Errors were reported based on the standard deviation from the mean of the Log EC50 values. Student's T-test was used to determine whether points were statistically different, using a two tailed test assuming normal distribution.
Cell infection with Francisella strains
J774A.1 cells and A549 cells were plated (105/well) in a 96-well plate and infected with either F. novicida, F. philomiragia, F. tularensis LVS, or F. novicida transposon mutants at MOI 500 for 2 hour incubation. Extracellular bacteria were removed by washing cell wells twice with DMEM for J774A.1 cells or Ham's F-12 for A549 cells. After Francisella infection and removal of extracellular bacterium, cells were incubated with 50 μg/ml gentamicin for 1 hour to eliminate extracellular bacterium but which does not affect intracellular bacteria. Cells were washed with media twice and incubated with Az in the media at final concentrations of 0, 0.1, 5, 15, 25, and 35 μg/ml for 0 or 22 hours at 37°C.
Quantification of intracellular Francisella bacteria
After exposure of cells to Francisella and antibiotics, the numbers of intracellular bacteria were determined. At 0 and 22 hours, the samples were washed twice with PBS. Sterile deionized water was used to lyse cells. Aliquots of cells and cell-associated bacteria were serially diluted onto chocolate agar plates, incubated at 37°C and 5% CO2 for 1 or 2 days and the CFU were counted.
Quantification of cellular apoptosis
Galleria mellonella exposure to Francisella strains and treatment with antibiotics
Galleria mellonella was obtained at the larval stages from Vanderhorst Wholesale (Saint Marys, OH). 10 caterpillars with a weight of 0.30-0.35 g were used for each group. Injection area was cleaned with water and a 10 μl Hamilton syringe was used to inject 10 μl of 3 × 106 CFU/ml of either F. novicida or F. tularensis LVS into the hemocoel of each caterpillar via the last left proleg and incubated at 37°C for 2 hours . Caterpillars were then injected with 10 μl of either PBS, 25 μg/ml Az, or 20 μg/ml ciprofloxacin in the last right proleg. Control caterpillars were either not injected or injected with only PBS, azithromycin, or ciprofloxacin. Caterpillar groups were incubated at 37°C and scored daily for color change or death.
This work was partially supported by funds from the College of Science, George Mason University. Dr Steven D. Nathan, Director of the Advanced Lung Disease Program and the Medical Director of the Lung Transplant Program at Inova Fairfax Hospital, Fairfax, VA contributed helpful discussions about the use of azithromycin in lung transplant patients.
- Sjostedt A: Tularemia: history, epidemiology, pathogen physiology, and clinical manifestations. Ann N Y Acad Sci. 2007, 1105: 1-29. 10.1196/annals.1409.009.View ArticlePubMedGoogle Scholar
- Keim P, Johansson A, Wagner DM: Molecular epidemiology, evolution, and ecology of Francisella. Ann N Y Acad Sci. 2007, 1105: 30-66. 10.1196/annals.1409.011.View ArticlePubMedGoogle Scholar
- Forsman M, Sandstrom G, Jaurin B: Identification of Francisella species and discrimination of type A and type B strains of F. tularensis by 16S rRNA analysis. Appl Environ Microbiol. 1990, 56: 949-955.PubMed CentralPubMedGoogle Scholar
- Nano FE, Zhang N, Cowley SC, Klose KE, Cheung KK, Roberts MJ, Ludu JS, Letendre GW, Meierovics AI, Stephens G, Elkins KL: A Francisella tularensis pathogenicity island required for intramacrophage growth. J Bacteriol. 2004, 186: 6430-6436. 10.1128/JB.186.19.6430-6436.2004.PubMed CentralView ArticlePubMedGoogle Scholar
- Biegeleisen JZ, Moody MD: Sensitivity in vitro of eighteen strains of Pasteurelia tularensis to erythromycin. J Bacteriol. 1960, 79: 155-156.PubMed CentralPubMedGoogle Scholar
- Olsufjev NG, Meshcheryakova IS: Infraspecific taxonomy of tularemia agent Francisella tularensis McCoy et Chapin. J Hyg Epidemiol Microbiol Immunol. 1982, 26: 291-299.PubMedGoogle Scholar
- Bossi P, Tegnell A, Baka A, Van Loock F, Hendriks J, Werner A, Maidhof H, Gouvras G: Bichat guidelines for the clinical management of tularaemia and bioterrorism-related tularaemia. Euro Surveill. 2004, 9: E9-10.PubMedGoogle Scholar
- Hardy DJ, Hensey DM, Beyer JM, Vojtko C, McDonald EJ, Fernandes PB: Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides. Antimicrob Agents Chemother. 1988, 32: 1710-1719.PubMed CentralView ArticlePubMedGoogle Scholar
- Vaara M: Outer membrane permeability barrier to azithromycin, clarithromycin, and roxithromycin in gram-negative enteric bacteria. Antimicrob Agents Chemother. 1993, 37: 354-356.PubMed CentralView ArticlePubMedGoogle Scholar
- Thomas RM, Titball RW, Oyston PC, Griffin K, Waters E, Hitchen PG, Michell SL, Grice ID, Wilson JC, Prior JL: The immunologically distinct O antigens from Francisella tularensis subspecies tularensis and Francisella novicida are both virulence determinants and protective antigens. Infect Immun. 2007, 75: 371-378. 10.1128/IAI.01241-06.PubMed CentralView ArticlePubMedGoogle Scholar
- Piddock LJ: Multidrug-resistance efflux pumps - not just for resistance. Nat Rev Microbiol. 2006, 4: 629-636. 10.1038/nrmicro1464.View ArticlePubMedGoogle Scholar
- Gil H, Platz GJ, Forestal CA, Monfett M, Bakshi CS, Sellati TJ, Furie MB, Benach JL, Thanassi DG: Deletion of TolC orthologs in Francisella tularensis identifies roles in multidrug resistance and virulence. Proc Natl Acad Sci USA. 2006, 103: 12897-12902. 10.1073/pnas.0602582103.PubMed CentralView ArticlePubMedGoogle Scholar
- Kobayashi N, Nishino K, Yamaguchi A: Novel macrolide-specific ABC-type efflux transporter in Escherichia coli. J Bacteriol. 2001, 183: 5639-5644. 10.1128/JB.183.19.5639-5644.2001.PubMed CentralView ArticlePubMedGoogle Scholar
- Chollet R, Chevalier J, Bryskier A, Pages JM: The AcrAB-TolC pump is involved in macrolide resistance but not in telithromycin efflux in Enterobacter aerogenes and Escherichia coli. Antimicrob Agents Chemother. 2004, 48: 3621-3624. 10.1128/AAC.48.9.3621-3624.2004.PubMed CentralView ArticlePubMedGoogle Scholar
- Bina XR, Lavine CL, Miller MA, Bina JE: The AcrAB RND efflux system from the live vaccine strain of Francisella tularensis is a multiple drug efflux system that is required for virulence in mice. FEMS Microbiol Lett. 2008, 279: 226-233. 10.1111/j.1574-6968.2007.01033.x.View ArticlePubMedGoogle Scholar
- Qin A, Scott DW, Mann BJ: Francisella tularensis subsp. tularensis Schu S4 disulfide bond formation protein B, but not an RND-type efflux pump, is required for virulence. Infect Immun. 2008, 76: 3086-3092. 10.1128/IAI.00363-08.PubMed CentralView ArticlePubMedGoogle Scholar
- Ferwerda A, Moll HA, Hop WC, Kouwenberg JM, Tjon Pian Gi CV, Robben SG, de Groot R: Efficacy, safety and tolerability of 3 day azithromycin versus 10 day co-amoxiclav in the treatment of children with acute lower respiratory tract infections. J Antimicrob Chemother. 2001, 47: 441-446. 10.1093/jac/47.4.441.View ArticlePubMedGoogle Scholar
- Amsden GW: Advanced-generation macrolides: tissue-directed antibiotics. Int J Antimicrob Agents. 2001, 18 (Suppl 1): S11-15. 10.1016/S0924-8579(01)00410-1.View ArticlePubMedGoogle Scholar
- Lai XH, Sjostedt A: Delineation of the molecular mechanisms of Francisella tularensis-induced apoptosis in murine macrophages. Infect Immun. 2003, 71: 4642-4646. 10.1128/IAI.71.8.4642-4646.2003.PubMed CentralView ArticlePubMedGoogle Scholar
- Telepnev M, Golovliov I, Sjostedt A: Francisella tularensis LVS initially activates but subsequently down-regulates intracellular signaling and cytokine secretion in mouse monocytic and human peripheral blood mononuclear cells. Microb Pathog. 2005, 38: 239-247. 10.1016/j.micpath.2005.02.003.View ArticlePubMedGoogle Scholar
- Baron GS, Nano FE: MglA and MglB are required for the intramacrophage growth of Francisella novicida. Mol Microbiol. 1998, 29: 247-259. 10.1046/j.1365-2958.1998.00926.x.View ArticlePubMedGoogle Scholar
- Hall JD, Craven RR, Fuller JR, Pickles RJ, Kawula TH: Francisella tularensis replicates within alveolar type II epithelial cells in vitro and in vivo following inhalation. Infect Immun. 2007, 75: 1034-1039. 10.1128/IAI.01254-06.PubMed CentralView ArticlePubMedGoogle Scholar
- Han S, Bishop BM, van Hoek ML: Antimicrobial activity of human beta-defensins and induction by Francisella. Biochem Biophys Res Commun. 2008, 371: 670-674. 10.1016/j.bbrc.2008.04.092.View ArticlePubMedGoogle Scholar
- Craven RR, Hall JD, Fuller JR, Taft-Benz S, Kawula TH: Francisella tularensis invasion of lung epithelial cells. Infect Immun. 2008, 76: 2833-2842. 10.1128/IAI.00043-08.PubMed CentralView ArticlePubMedGoogle Scholar
- Aperis G, Fuchs BB, Anderson CA, Warner JE, Calderwood SB, Mylonakis E: Galleria mellonella as a model host to study infection by the Francisella tularensis live vaccine strain. Microbes Infect. 2007, 9: 729-734. 10.1016/j.micinf.2007.02.016.PubMed CentralView ArticlePubMedGoogle Scholar
- Seed KD, Dennis JJ: Development of Galleria mellonella as an alternative infection model for the Burkholderia cepacia complex. Infect Immun. 2008, 76: 1267-1275. 10.1128/IAI.01249-07.PubMed CentralView ArticlePubMedGoogle Scholar
- Ikaheimo I, Syrjala H, Karhukorpi J, Schildt R, Koskela M: In vitro antibiotic susceptibility of Francisella tularensis isolated from humans and animals. J Antimicrob Chemother. 2000, 46: 287-290. 10.1093/jac/46.2.287.View ArticlePubMedGoogle Scholar
- Urich SK, Petersen JM: In vitro susceptibility of isolates of Francisella tularensis types A and B from North America. Antimicrob Agents Chemother. 2008, 52: 2276-2278. 10.1128/AAC.01584-07.PubMed CentralView ArticlePubMedGoogle Scholar
- Mason WL, Eigelsbach HT, Little SF, Bates JH: Treatment of tularemia, including pulmonary tularemia, with gentamicin. Am Rev Respir Dis. 1980, 121: 39-45.PubMedGoogle Scholar
- Lai XH, Golovliov I, Sjostedt A: Francisella tularensis induces cytopathogenicity and apoptosis in murine macrophages via a mechanism that requires intracellular bacterial multiplication. Infect Immun. 2001, 69: 4691-4694. 10.1128/IAI.69.7.4691-4694.2001.PubMed CentralView ArticlePubMedGoogle Scholar
- Saha S, Savage PB, Bal M: Enhancement of the efficacy of erythromycin in multiple antibiotic-resistant gram-negative bacterial pathogens. J Appl Microbiol. 2008, 105: 822-828. 10.1111/j.1365-2672.2008.03820.x.View ArticlePubMedGoogle Scholar
- Marinov KT, Georgieva ED, Ivanov IN, Kantardjiev TV: Characterization and genotyping of strains of Francisella tularensis isolated in Bulgaria. J Med Microbiol. 2009, 58: 82-85. 10.1099/jmm.0.003426-0.View ArticlePubMedGoogle Scholar
- Pechere JC: Macrolide resistance mechanisms in Gram-positive cocci. Int J Antimicrob Agents. 2001, 18 (Suppl 1): S25-28. 10.1016/S0924-8579(01)00407-1.View ArticlePubMedGoogle Scholar
- Larsson P, Oyston PC, Chain P, Chu MC, Duffield M, Fuxelius HH, Garcia E, Halltorp G, Johansson D, Isherwood KE: The complete genome sequence of Francisella tularensis, the causative agent of tularemia. Nat Genet. 2005, 37: 153-159. 10.1038/ng1499.View ArticlePubMedGoogle Scholar
- Champion MD, Zeng Q, Nix EB, Nano FE, Keim P, Kodira CD, Borowsky M, Young S, Koehrsen M, Engels R: Comparative genomic characterization of Francisella tularensis strains belonging to low and high virulence subspecies. PLoS Pathog. 2009, 5: e1000459-10.1371/journal.ppat.1000459.PubMed CentralView ArticlePubMedGoogle Scholar
- Piddock LJ: Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. Clin Microbiol Rev. 2006, 19: 382-402. 10.1128/CMR.19.2.382-402.2006.PubMed CentralView ArticlePubMedGoogle Scholar
- Misra R, Reeves PR: Role of micF in the tolC-mediated regulation of OmpF, a major outer membrane protein of Escherichia coli K-12. J Bacteriol. 1987, 169: 4722-4730.PubMed CentralPubMedGoogle Scholar
- Biswas S, Raoult D, Rolain JM: A bioinformatic approach to understanding antibiotic resistance in intracellular bacteria through whole genome analysis. Int J Antimicrob Agents. 2008, 32: 207-220. 10.1016/j.ijantimicag.2008.03.017.View ArticlePubMedGoogle Scholar
- Kraemer PS, Mitchell A, Pelletier MR, Gallagher LA, Wasnick M, Rohmer L, Brittnacher MJ, Manoil C, Skerett SJ, Salama NR: Genome-wide screen in Francisella novicida for genes required for pulmonary and systemic infection in mice. Infect Immun. 2009, 77: 232-244. 10.1128/IAI.00978-08.PubMed CentralView ArticlePubMedGoogle Scholar
- Norcia LJ, Silvia AM, Santoro SL, Retsema J, Letavic MA, Bronk BS, Lundy KM, Yang B, Evans NA, Hayashi SF: In vitro microbiological characterization of a novel azalide, two triamilides and an azalide ketal against bovine and porcine respiratory pathogens. J Antibiot (Tokyo). 2004, 57: 280-288.View ArticleGoogle Scholar
- Weiss DS, Brotcke A, Henry T, Margolis JJ, Chan K, Monack DM: In vivo negative selection screen identifies genes required for Francisella virulence. Proc Natl Acad Sci USA. 2007, 104: 6037-6042. 10.1073/pnas.0609675104.PubMed CentralView ArticlePubMedGoogle Scholar
- Raynaud C, Meibom KL, Lety MA, Dubail I, Candela T, Frapy E, Charbit A: Role of the wbt locus of Francisella tularensis in lipopolysaccharide O-antigen biogenesis and pathogenicity. Infect Immun. 2007, 75: 536-541. 10.1128/IAI.01429-06.PubMed CentralView ArticlePubMedGoogle Scholar
- Cowley SC, Gray CJ, Nano FE: Isolation and characterization of Francisella novicida mutants defective in lipopolysaccharide biosynthesis. FEMS Microbiol Lett. 2000, 182: 63-67. 10.1111/j.1574-6968.2000.tb08874.x.View ArticlePubMedGoogle Scholar
- Shapiro DS, Schwartz DR: Exposure of laboratory workers to Francisella tularensis despite a bioterrorism procedure. J Clin Microbiol. 2002, 40: 2278-2281. 10.1128/JCM.40.6.2278-2281.2002.PubMed CentralView ArticlePubMedGoogle Scholar
- Hassoun A, Spera R, Dunkel J: Tularemia and once-daily gentamicin. Antimicrob Agents Chemother. 2006, 50: 824-10.1128/AAC.50.2.824.2006.PubMed CentralView ArticlePubMedGoogle Scholar
- Harrell RE, Simmons HF: Pleuropulmonary tularemia: successful treatment with erythromycin. South Med J. 1990, 83: 1363-1364.View ArticlePubMedGoogle Scholar
- Westerman EL, McDonald J: Tularemia pneumonia mimicking legionnaires' disease: isolation of organism on CYE agar and successful treatment with erythromycin. South Med J. 1983, 76: 1169-1170.View ArticlePubMedGoogle Scholar
- Mizunoe S, Kadota J, Tokimatsu I, Kishi K, Nagai H, Nasu M: Clarithromycin and azithromycin induce apoptosis of activated lymphocytes via down-regulation of Bcl-xL. Int Immunopharmacol. 2004, 4: 1201-1207. 10.1016/j.intimp.2004.05.011.View ArticlePubMedGoogle Scholar
- Platz GJ, Bublitz DC, Mena P, Benach JL, Furie MB, Thanassi DG: A tolC Mutant of Francisella tularensis Is Hypercytotoxic Compared to the Wild Type and Elicits Increased Proinflammatory Responses from Host Cells. Infect Immun. 78: 1022-1031. 10.1128/IAI.00992-09.Google Scholar
- Hoyt JC, Robbins RA: Macrolide antibiotics and pulmonary inflammation. FEMS Microbiol Lett. 2001, 205: 1-7. 10.1111/j.1574-6968.2001.tb10917.x.View ArticlePubMedGoogle Scholar
- Fietta AM, Meloni F: Lung transplantation: the role of azithromycin in the management of patients with bronchiolitis obliterans syndrome. Curr Med Chem. 2008, 15: 716-723. 10.2174/092986708783885228.View ArticlePubMedGoogle Scholar
- Johansson A, Berglund L, Gothefors L, Sjostedt A, Tarnvik A: Ciprofloxacin for treatment of tularemia in children. Pediatr Infect Dis J. 2000, 19: 449-453. 10.1097/00006454-200005000-00011.View ArticlePubMedGoogle Scholar
- Zimpfer A, Propst A, Mikuz G, Vogel W, Terracciano L, Stadlmann S: Ciprofloxacin-induced acute liver injury: case report and review of literature. Virchows Arch. 2004, 444: 87-89. 10.1007/s00428-003-0917-9.View ArticlePubMedGoogle Scholar
- Dichiara AJ, Atkinson M, Goodman Z, Sherman KE: Ciprofloxacin-induced acute cholestatic liver injury and associated renal failure. Case report and review. Minerva Gastroenterol Dietol. 2008, 54: 307-315.PubMedGoogle Scholar
- Akita H, Sato Y, Kusumoto Y, Iwata S, Takeuchi Y, Aoyama T, Yokota T, Sunakawa K: Bacteriological, pharmacokinetic and clinical evaluation of azithromycin in the pediatric field. Jpn J Antibiot. 1996, 49: 899-916.PubMedGoogle Scholar
- Gallagher LA, Ramage E, Jacobs MA, Kaul R, Brittnacher M, Manoil C: A comprehensive transposon mutant library of Francisella novicida, a bioweapon surrogate. Proc Natl Acad Sci USA. 2007, 104: 1009-1014. 10.1073/pnas.0606713104.PubMed CentralView ArticlePubMedGoogle Scholar
- Bauer AW, Kirby WM, Sherris JC, Turck M: Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol. 1966, 45: 493-496.PubMedGoogle Scholar
- Baker CN, Hollis DG, Thornsberry C: Antimicrobial susceptibility testing of Francisella tularensis with a modified Mueller-Hinton broth. J Clin Microbiol. 1985, 22: 212-215.PubMed CentralPubMedGoogle Scholar
- Pos KM: Trinity revealed: Stoichiometric complex assembly of a bacterial multidrug efflux pump. Proc Natl Acad Sci USA. 2009, 106: 6893-6894.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.